What does an intrathecal pain pump treat?

A pill travels through the gut, the liver and the bloodstream. Only a fraction of it ever reaches a spinal receptor. An intrathecal pump skips that whole route. A catheter (thin tube) placed in the intrathecal space delivers the drug right where the receptors live. That means the dose that works can be a hundredth or less of the oral dose. That is the whole case for the device: not more drug, far less, aimed with more precision.

Two groups make up almost everyone who ends up with one. The first is refractory cancer pain (pain that has stopped responding to treatment). Here the disease or the side effects of treatment have made pills too hard to take or too weak. The second is selected refractory non-cancer pain — failed back surgery syndrome, severe spasticity, or complex regional pain syndrome that has not responded to less invasive interventional steps. The goal there is lasting control at a fraction of the whole-body burden.

Is there a trial before the pump is implanted?

Nobody gets a permanent pump on a first visit. A trial dose comes first, either through a temporary catheter or a single injection. We measure what it actually does to pain and function over the next hours to days. A trial that fails is not a failed patient. It is the system doing its job, keeping a permanent implant out of someone it was not going to help.

What medications go in a pain pump?

Who is not a candidate

An uncontrolled bleeding disorder, active body-wide infection, or anatomy that will not fit the catheter rules the device out. So does a failed trial. Beyond those, a patient whose pain source has not been found is not a candidate. A pump is not a diagnostic tool. Implanting one into an unclear picture usually just adds hardware to a problem that was never mapped.

How often does a pain pump need a refill?

We refill the reservoir through the skin in the office. The pump’s size and your dose set the timing, typically every one to three months. This is a scheduled visit, not a symptom-driven one. Running the reservoir dry is a real risk, with real withdrawal or breakthrough pain depending on the drug. So the practice tracks refill timing; it is not left to memory. Battery life and function are checked at the same visit. Most pumps are rated for several years before the device itself needs replacement.

The terrain around a pump

Two facts of biology make the terrain matter here as much as anywhere else in this practice. Long-term systemic (whole-body) opioid exposure itself drives inflammatory and hormone changes — lower testosterone, broken sleep, worse insulin sensitivity. A pump’s lower total dose can partly reverse these, but it does not fix them on its own. And spasticity or refractory pain this severe is disabling. It isolates people from work and from each other, and that is its own driver of the pain, not a side note to it. This practice pairs a pump with the same behavior and metabolic work — see sleep, movement and behavior — used everywhere else here, because the device changes the dose, not the whole disease.

The evidence, honestly

The trial that set this therapy’s place in refractory cancer pain is now more than two decades old. It was a randomized comparison of implantable drug delivery against comprehensive medical management (full standard medical care). The pump group had better pain control, less drug-related toxicity, and a survival advantage at six months. That striking result has not needed repeating because the mechanism and the finding both held up. For spasticity, systematic reviews of intrathecal baclofen in spinal cord injury and multiple sclerosis consistently show meaningful drops in spasticity scores. The same reviews note that functional gains — walking, transfers, independence — vary more. They depend heavily on the rehab built around the device, not the device alone.

The research is thinner on long-term, non-cancer pain results beyond a few years. That gap is why polyanalgesic consensus guidelines exist. They set common rules for drug choice, dosing and screening. The evidence base here rests more on built-up multi-center experience than on large placebo-controlled trials. Those trials are hard to run ethically once a therapy is this invasive. We tell patients that directly. This is a well-established mechanism with a truly strong cancer-pain trial behind it. The non-cancer use is backed by consensus and long clinical experience rather than an equal trial of its own.

What happens on the day

What are the risks and disadvantages of a pain pump?

This is a surgical implant, and it carries surgical risks — infection, bleeding, a spinal fluid leak causing a headache when you sit or stand. Catheter problems (kinking, migration, blockage) can cause symptoms to suddenly return. More seriously, they can cause a withdrawal reaction if the drug abruptly stops reaching the space; that is treated as urgent. Device failure is uncommon, but it is why refills and checks happen on a fixed schedule rather than as needed. This practice implants pumps directly, and you hear the real list from us rather than discover it later.

Common questions

Related reading

• Spinal cord stimulation
• Failed back surgery syndrome
• Opioid stewardship
• Complex regional pain syndrome
• When injections stop working